Navigation Links
Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso
Date:12/29/2008

REHOVOT, Israel, JERSEY CITY, New Jersey and PHILADELPHIA, Pennsylvania, December 29 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG), the leading developer of microRNA-based molecular diagnostics, announced today the introduction of its third diagnostic test, miRview(TM) meso. The test is now commercially available through Rosetta Genomics CLIA-certified lab in Philadelphia.

To order the test, physicians may contact 1-888-522-7971, or visit the company's website http://www.rosettagenomics.com.

"I am very excited to finally see a molecularly-based test that can objectively differentiate mesothelioma from several types of carcinomas in the lung with such high level of accuracy" noted Harvey Pass, MD, Division Chief for Thoracic Surgery and Thoracic Oncology at the New York University Langone Medical Center. "Ruling out Mesothelioma from lung cancer for individuals that were exposed to asbestos can be difficult and challenging. I am sure that this test will become an important tool for both oncologists and pathologists in obtaining the right diagnosis in these patients."

Malignant pleural mesothelioma is directly linked to exposure to asbestos particles, as well as to various heavy metals. Rescue workers, shipyard workers, and miners are at increased risk of developing mesothelioma. Currently, there is no single diagnostic test that is entirely conclusive for this differentiation. In addition, pathological diagnosis may suffer from significant inter-observer variability, and in the absence of a single specific and reliable test, mesothelioma can be difficult to identify from other cancers.

miRview(TM) meso differentiates mesothelioma, a cancer connected to asbestos exposure, from other carcinomas in the lung. Currently, there is no single diagnostic test that is entirely conclusive for this differe
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2008 Healthcare Conference
2. Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS
3. Rosetta Genomics Announces Conference Call and Webcast of Third Quarter Financial Results
4. /C O R R E C T I O N -- Rosetta Genomics Ltd/
5. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) Centennial Conference
6. Rosetta Genomics to Present at Oppenheimers 19th Annual Healthcare Conference
7. Credit Suisse Repurchases Auction Rate Securities (ARS) From Rosetta Genomics
8. Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative
9. Rosetta Genomics to Present at the Upcoming EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer"
10. Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targets for HIV
11. Rosetta Genomics Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Best Sanitizers, Inc., the first company ... sanitizer, asks food processors and food handling professionals to ... they’re currently using to Best Sanitizers’ Alpet® E3 ... to fighting cross-contamination and the spread of pathogens in ... are key criteria that make a hand sanitizer most ...
(Date:8/28/2014)... in spintronics, an electronic which is not only ... on their spin and the spin-related magnetism. Spin-charge ... signals and vice versa. Recently, the research group ... Physics at Johannes Gutenberg University Mainz in collaboration ... has for the first time realised a new, ...
(Date:8/28/2014)... executives from clinical trial marketing firm BBK Worldwide will lead ... Clinical Trials 2014 , to be held at the Hyatt ... Patient recruitment experts Bonnie A. Brescia , Matthew ... on the benefits of employing an effective patient engagement strategy, ... mobile apps – can be used to drive study participation ...
(Date:8/28/2014)... Aug. 28, 2014  Armetheon, Inc. ( www.armetheon.com ... mid- to late-stage cardiovascular drug candidates, today announced ... first round of financing. The Series A round ... Bioventures with participation from investors that included Atheneos ... Dr. Larry Hsu , the founder of ...
Breaking Biology Technology:Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3A new, tunable device for spintronics 2A new, tunable device for spintronics 3BBK Worldwide Leads Sessions at Key September Events 2Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3
... Top 25 Global Pharmaceutical Companies Select Drug ... Visualization, MOUNTAIN VIEW, Calif., April 2, 2008 ... provider of software,strategic consulting, and regulatory services for ... 25 global pharmaceutical,companies have become customers for its ...
... 1, 2008 MiMedx Group, Inc.,(OTC Bulletin Board: ... AYXC), today reported that the contemplated reverse stock ... related name change, to,MiMedx Group, Inc., was approved ... a result of the reverse split and redomestication, ...
... Installation and Major Data Migration in ... United States and Abroad, CHICAGO, April 1, ... signed an agreement with the Cleveland,Clinic, a not-for-profit ... deploy the syngo(R) Dynamics cardiology image,management and reporting ...
Cached Biology Technology:Pharsight Signs Two New DMX(R) License Customers 2Pharsight Signs Two New DMX(R) License Customers 3MiMedx Group Announces Post-split Name Change 2MiMedx Group Announces Post-split Name Change 3Siemens Signs Multi-Year Agreement With Cleveland Clinic to Deploy Enterprise-Wide Cardiology PACS 2
(Date:8/31/2014)... have discovered that ,good, cholesterol is turned ,bad, by ... MG, was found to damage ,good, HDL cholesterol, which ... , Low levels of HDL, High Density Lipoprotein, ... of MG being common in the elderly and those ... funding from the British Heart Foundation (BHF) and published ...
(Date:8/31/2014)... of satellite data from the last 19 years reveals that ... the coast of Antarctica to rise by 2cm more than ... of Southampton detected the rapid rise in sea-level by studying ... million square kilometres. , The melting of the ... has contributed an excess of around 350 gigatonnes of freshwater ...
(Date:8/29/2014)... SAN ANTONIO (Aug. 29, 2014) Scientists at the ... the School of Medicine at the UT Health Science ... longevity in the tissues of the longest-lived rodent, the ... factor in the cells of naked mole rats protects ... disposer for damaged and obsolete proteins. , The factor ...
Breaking Biology News(10 mins):Sugar substance 'kills' good HDL cholesterol, new research finds 2Factor in naked mole rat's cells enhances protein integrity 2
... turtles are too optimistic, according to Loren McClenachan ... McClenachan, Jeremy Jackson and Marah Newman agree ... helped increase green and hawksbill turtle populations that ... that dwindling turtle populations on many historically important ...
... population in New Hampshire's Great Bay estuary has plummeted by ... disease MSX. The previous century saw a slower but equally ... local extinction on some reefs," says Ray Grizzle, research associate ... , Now Grizzle is working to bring oysters back ...
... a surprisingly high percentage of people with type 1 ... years or longer (The Joslin Medalists) may still have ... The findings will be presented June 12 at the ... Washington, D.C. , "It is surprising that some ...
Cached Biology News:All the eggs in one basket 2All the eggs in one basket 3UNH researcher restoring oyster reefs to Great Bay 2Joslin discovers signs of residual islet cell function in people with long-term type 1 diabetes 2Joslin discovers signs of residual islet cell function in people with long-term type 1 diabetes 3
Rabbit polyclonal to Somatostatin 28 ( Abpromise for all tested applications). entrezGeneID: 6750 SwissProtID: P61278...
... Features Convenient platform for tube ... - 96 x 0.2ml V-bottom tubes ... Thermo-Tube Plates - Thermo-Fast® 96 Non-Skirted ... - 48 x 0.5ml Thermo-Tubes Multiple ...
... Pro upgrade for Shimadzu Phoretix 2D, Expression ... statistical tools for comparative gel analysis studies ... Data base add on component ... version 9i release 2 client software). ...
... systems provide linking and labelling reagents ... specific primary antibodies for visualising cellular ... accomplished using an ultra-sensitive indirect labelling ... technology. Secondary antibodies are polymerised directly ...
Biology Products: